Abstract 2866
Background
In the Netherlands, hospice care is provided in professional-driven hospices and volunteer-driven hospices. To date, insight is lacking whether the care provided in hospices is appropriate to meet the patient’s needs and wishes. The aim is to gain insight into the characteristics of patients admitted in hospices, their needs and wishes and the care they receive.
Methods
A retrospective patient record study of 1200 hospice patients in the Netherlands. Preliminary results are shown for the first 203 patients. Inclusion criteria are deceased, adult patients admitted in hospice in 2017-2018.The following outcomes were included: Patient characteristics: demographics, disease characteristics, multidimensional symptoms, needs and wishes. Care characteristics: measurement instruments and multidimensional care. Descriptive statistisc was used for analyses.
Results
Preliminary results of 203 patients (mean age 74.8 years, 51.8% woman, 84% cancer diagnoses) from 13 hospices show that initiative for admission is mostly taken by the patient or their family (65.7%). Reasons for admission were described as physical symptoms (73.1%), preferred location of dying (16.1%) and social problems (9.7%). Patients were mostly admitted for last-resort (96.4%) and most patients were in the phase of symptom palliation (79.4%). Problems that were most described were delirium (18.6%), decubitus (12.4%) and edema (6.2%). On average, 10.6 interventions were performed in the first 72 hours per patient. Most were within the physical dimension (76.6%) and least in the social dimension (2.3%). Of the 11 different measurement tools identified, a symptom diary (20.7%) and a palliative assessment (17.2%) were most frequent used.
Conclusions
A preliminary overview of hospice patients and the care they receive was presented. The study is work in progress. Additional data and a comparison between organizational structures of hospices will be presented during the congress.
Clinical trial identification
Editorial acknowledgement
R. Koorn, F. van der Baan, E. de Graaf, S. Teunissen.
Legal entity responsible for the study
S.C.C.M. Teunissen.
Funding
ZonMw.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1707 - Clinical utility of precision immunoprofiling and monitoring of the tumor microenvironment using flow cytometry and CyTOF in patients with advanced NSCLC treated with atezolizumab: results from a phase II study for biomarker analysis (EPOC1702)
Presenter: Keisuke Kirita
Session: Poster Display session 3
Resources:
Abstract
3594 - Tumor mutation burden (TMB), PD-L1, IFN-γ signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
744 - The decrease of TMB, TNB and HLA expression are the Mechanism of Drug Resistance of NSCLC to immunosuppressive PD-1/PD-l1.
Presenter: Sheng Yu
Session: Poster Display session 3
Resources:
Abstract
2350 - Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
Presenter: Rika Kizawa
Session: Poster Display session 3
Resources:
Abstract
5930 - A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumors.
Presenter: Javier Pérez-peña
Session: Poster Display session 3
Resources:
Abstract
6127 - Alterations of TMB and TCR repertoires during Chemotherapy in East Asian lung cancer patients without TKI-related driver gene mutations
Presenter: Lele Song
Session: Poster Display session 3
Resources:
Abstract
1310 - Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody.
Presenter: Motoo Nomura
Session: Poster Display session 3
Resources:
Abstract
2286 - Extracellular matrix and tissue derived metabolites in a liquid biopsy identifies endotypes of metastatic melanoma patients with differential response to immune checkpoint inhibitor treatment
Presenter: Nicholas Willumsen
Session: Poster Display session 3
Resources:
Abstract
4107 - Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy
Presenter: Julie Stein
Session: Poster Display session 3
Resources:
Abstract
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract